ReviewMaterials today. Bio2025
Nanotechnology-driven advancements in organ transplantation: Multifaceted strategies for organ preservation, ischemia reperfusion injury, immunomodulation and post-transplant monitoring.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Whole ovary cryopreservation and transplantation: a narrative review of technological advances, biological hurdles, and clinical translation in fertility preservation.Journal of assisted reproduction and genetics · 2026Review
- Advances in nanomaterial-based delivery systems for inducing transplantation tolerance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organ transplantation faces critical challenges, including donor shortages, suboptimal preservation, ischemia-reperfusion injury (IRI), and immune rejection. Nanotechnology offers transformative solutions by leveraging precision-engineered materials to enhance graft viability and outcomes. This review highlights nanomaterials' roles in revolutionizing organ preservation. Nanoscale oxygen carriers, such as perfluorocarbon-based systems, address hypoxia by improving graft oxygenation and angiogenesis. Advanced drug delivery systems enable targeted immunosuppression, reducing systemic toxicity while enhancing therapeutic efficacy. Antioxidant and antimicrobial nanomaterials integrated into preservation solutions mitigate oxidative stress and microbial contamination during storage. Additionally, nanotechnology facilitates real-time monitoring of graft rejection via biosensing platforms, enabling early intervention. Despite preclinical successes in renal, hepatic, and pancreatic islet models, clinical translation requires resolving challenges like nanoparticle biodistribution, biocompatibility, and scalability for human organs. By bridging material science and transplantation medicine, nanotechnology redefines organ viability criteria, extends preservation windows, and expands donor pools. This synthesis of interdisciplinary innovations positions nanomaterials as pivotal tools for achieving the next paradigm shift in transplant outcomes, emphasizing urgent clinical translation to address unmet needs in global healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.